Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Hyundai Motor Company

Kia Motors Corporation

Hanmi Holdings Co., Ltd.

Hammi Holdings Co., Ltd

Jaeheon Lee

Gwan Sun Lee

Young-Kil Chang

Gha-Seung Park

Eun-Ju Park

Moonsub Lee

Han Kyong Kim

Jin Hee Kim

Eun Jung Lim

Chul Hyun Park

Hyo-Jeong Bang

Ji Eun Lee

Jae Chul Lee

Wootae Kim

Gwan-Sun Lee

Young Kil Chang

Chul-Hyun Park

Taewon Park

Cheol Kyung Kim

Tae Jin Choi

Gha Seung Park

Jaeho Yoo

Weon Ki Yang

Cheol Hyun Park

Sanghee Lee

Hoe Chul Lee

Yoon Ju Lee

Cheol Kyong Kim

Youngkil Chang

Gwansun Lee

Chulhyun Park

Dongsuk Chae

Kwangsik Yang

Changseok Oh

Kiwoong Song

Choong-Hahn Kim

Suk Man Jang

Yong-Hoon An

Chang-Ju Choi

Cheol-Kyong Kim

Jae-Chul Lee

Taehee Ha

Hoechul Lee

Eun-ju Park

Cheol-Kyong Sinnamusil Sinmyeong Apt 634-1003 Kim

Gha-Seung Sinjeongmaeul 1-Danji 107-1003 Park

Jae-Chul Kyungwonyeonlip Ra-Dong 101 Lee

The present invention is provided with one or more inserts that are inserted at the lower portion of a water jacket formed at siamese portions between cylinder bores of a cylinder block and increase the flow of cooling water at the upper portion of the water jacket, in order to provide a cooling device and an insert for a water jacket of an internal combustion engine, which is inserted at the lower portion of the water jacket formed at the siamese portions of the cylinder block to increase the flow of cooling water, improves cooling efficiency of the siamese portions of the cylinder block by inducting recirculation of the cooling water at the lower portion, and improves fuel efficiency by making the temperature uniform in the stroke direction of the piston of the cylinder block and reducing friction of the piston.

Cooling device and insert for water jacket of internal combustion engine

The present invention relates to a novel, high-yield and low-cost method for preparing entecavir, [1-S-(1&#x3b1;,3&#x3b1;,4&#x3b2;)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one, an antiviral agent, and novel intermediates used therein.

Intermediate and process for preparing entecavir using same

The present invention relates to a method for preparing Montelukast acid or its sodium salt by reacting a thiol compound with a Montelukast intermediate in the presence of a base in a medium comprising an ionic liquid compound. In accordance with the inventive method, highly pure Montelukast acid or its sodium salt, which is advantageously used as a raw material in the preparation of Montelukast, a leukotriene antagonist, can be easily prepared in a high yield.

Method for preparation of Montelukast acid in ionic liquid medium

The present invention relates to a method for preparing montelukast, an inhibitor against leukotrienes, and an intermediate used therein. According to the inventive method, high-purity montelukast or its sodium salt can be prepared in a high yield.

Method of preparing montelukast and intermediates used therein

The present invention relates to a method for preparing capecitabine and a method for preparing a &#x3b2;-anomer-rich trialkyl carbonate compound used therein, and a highly pure capecitabine can be efficiently prepared with a high yield by the method of the present invention using the &#x3b2;-anomer-rich trialkyl carbonate compound as an intermediate.

Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein

1-&#x3b1;-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative of formula (I) having the 3-hydroxy group protected with a biphenylcarbonyl group is a solid which can be easily purified by a simple procedure such as recrystallization, and therefore, it can be advantageously used as an intermediate in the preparation of gemcitabine in a large scale. Further, the 1-&#x3b1;-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative of formula (I) can be prepared with high stereoselectivity using the compound of formula (V) as an intermediate.

1-&#x3b1;-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereof

Provided is an improved method for stereoselectively preparing 2'-deoxy-2&#x2032;,2&#x2032;-difluorocytidine of formula (I), which includes reacting a 1-halo ribofuranose compound with a nucleobase of formula (IV) in a solvent to obtain a nucleo side of formula (II) with removal of a silyl halide ((alkyl)SiX (X=halide)); and deprotecting the nucleoside of formula (II) to obtain 2&#x2032;-deoxy-2&#x2032;,2&#x2032;-difluorocytidine of formula (I). 2&#x2032;-Deoxy-2&#x2032;,2&#x2032;-difluorocytidine of formula (I) is effective for treating various cancers such as non-small cell lung (NSCLC), pancreatic, bladder, breast or ovarian cancers. 

Method for the preparation of 2'-deoxy-2&#x2032;,2&#x2032;-difluorocytidine

3R-carboxylate enantiomer derivative of formula (III) can be prepared easily and selectively by the method of the present invention, and a highly pure D-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative can be prepared efficiently from the compound of formula (III) as an intermediate.

Method for the preparation of D-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative

Highly pure simvastatin can be prepared economically in a high yield using the method comprising the steps of treating lovastatin with potassium hydroxide dissolved in a mixture of water and methanol to obtain a triol acid; relactonizing the triol acid, and protecting the hydroxy group on the lactone ring; and acylating the resulting compound with 2,2-dimethylbutyryl chloride or 2,2-dimethylbutyryl bromide in the presence of an acylation catalyst in an organic solvent, followed by removing the silyl protecting group on the lactone ring to obtain simvastatin.

Process for the preparation of simvastatin

Growing community of inventors

Yongin-si, South Korea

Jaeheon Lee